Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE

AGLEAeglea BioTherapeutics, Inc. US flag

NASDAQ Global Market

12.01

USD

+0.75

- -

48.63MMarket Cap

Aeglea BioTherapeutics, Inc.

AGLE

(NASDAQ Global Market)

Recent

price

12.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Vaxcyte, Inc. (PCVX)
Microbix Biosystems Inc. (MBX.TO)
Tryp Therapeutics Inc. (TRYPF)
Celltrion Healthcare Co., Ltd. (091990.KQ)
MedPacto, Inc. (235980.KQ)
Brainstorm Cell Therapeutics Inc. (BCLI)
Business: Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel human enzyme therapeutics for rare metabolic diseases with limited treatment options. The company's core products include pegzilarginase, a recombinant human Arginase 1 enzyme in a pivotal Phase 3 trial for treatment of Arginase 1 Deficiency, and pegtarviliase, a polyethylene glycol-modified enzyme in Phase 1/2 trials for Classical Homocystinuria. Aeglea also has a preclinical candidate, AGLE-325, targeting cystinuria, though preclinical work on this and other unnamed pipeline programs has been halted to focus resources. The company specializes in enzyme-based therapies addressing amino acid metabolism disorders such as Argininemia and Hyperargininemia. Founded in 2013 and headquartered in Texas, Aeglea conducts its clinical development primarily in the United States. Recently, Aeglea BioTherapeutics has undergone significant strategic changes including a corporate restructuring to improve operational efficiency, resulting in workforce reductions and halting non-core preclinical programs to prioritize late-stage clinical assets. The company’s lead pegzilarginase therapy achieved the primary endpoint in its Phase 3 PEACE trial demonstrating arginine reduction efficacy and holds both Rare Pediatric Disease and Breakthrough Therapy Designations, with a Marketing Authorization Application under review by the European Medicines Agency. Additionally, in late 2023, Aeglea rebranded to Spyre Therapeutics, shifting its pipeline focus toward inflammatory bowel disease through its acquisition of Spyre Therapeutics, which brings antibody-based product candidates targeting α4β7 and TL1A for upcoming clinical studies in 2024, signaling a strategic expansion into immunology and IBD treatment domains. The company maintains partnerships with research institutions and biopharmaceutical firms and has expanded its executive leadership with industry veterans to support these new directions. Aeglea operates primarily in the biopharmaceutical and rare disease segments, targeting patients with rare metabolic and inflammatory disorders. Its product pipeline leverages advanced enzyme engineering and antibody technologies to develop treatments with improved efficacy and dosing convenience. The company’s commercial activities remain limited as it is clinical-stage, with financial support derived largely from equity funding, partnerships, and recent strategic alliances aimed at accelerating development efforts and market entry. Aeglea’s evolution toward Spyre Therapeutics marks a broadening of its therapeutic focus while maintaining a commitment to innovation in enzyme and biologic therapies for underserved patient populations.

Company News